Table 3.
Baseline characteristics of VMAT group and tomotherapy group in the pre- and post-PSM cohorts .
| pre-PSM | post-PSM | |||||
|---|---|---|---|---|---|---|
| VMAT (n = 61) | Tomotherapy (n = 110) | p | VMAT (n = 54) | Tomotherapy (n = 54) | p | |
| T stage | 0.006 | 0.560 | ||||
| T3 | 36 | 40 | 29 | 32 | ||
| T4 | 25 | 70 | 25 | 22 | ||
| N stage | 0.802 | 0.961 | ||||
| N0 | 2 | 3 | 2 | 2 | ||
| N1 | 14 | 32 | 12 | 14 | ||
| N2 | 28 | 49 | 25 | 25 | ||
| N3 | 17 | 26 | 15 | 13 | ||
| PGTVnx volume (cm3) | 119.98 ± 42.36 | 144.05 ± 52.93 | 0.003 | 126.74 ± 39.65 | 130.17 ± 37.58 | 0.646 |
| PGTVnd volume (cm3) | 87.90 ± 58.39 | 80.88 ± 61.94 | 0.470 | 88.53 ± 61.69 | 81.73 ± 57.37 | 0.554 |
VMAT, volumetric modulated arc therapy; PSM, propensity score matching; PGTVnx, planning target volume of the nasopharynx; PGTVnd, planning target volume of the lymph nodes.